Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cleft Care India Study: A National Audit on Patients with Non-Syndromic Unilateral Cleft Lip and Palate Patients. Part 2: Oral Health Outcomes.

The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association·2026
Same author

Indiacran: An Intercentre Assessment of Craniofacial Form for Patients With Repaired Complete Unilateral Cleft Lip and Palate.

Orthodontics & craniofacial research·2026
Same author

Cleft Care India Study: A National Audit on Patients with Non-Syndromic Unilateral Cleft Lip and Palate Patients. Part 1: Background, Skeletal, Dental Arch, and Nasolabial Outcomes.

The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association·2026
Same author

Clinical Data Analysis Identifies Prognostic Long Non-coding RNA Signatures in Lung Adenocarcinoma.

Cancer genomics & proteomics·2026
Same author

Cleft Care India Study: A National Audit on Patients with Non-Syndromic Unilateral Cleft Lip and Palate: Surgical Procedures and Outcomes.

The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association·2026
Same author

Development and Preliminary Psychometric Evaluation of Agni Assessment Scale: A Measure of Functional Digestive Capacity Based on Ayurveda.

Complementary medicine research·2026

Related Experiment Video

Updated: May 2, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.9K

Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study.

Shashi Kumar Bhasker1, Sandeep Saxena1, Kamlesh Singh1

  • 1King George's Medical University, Lucknow, Uttar Pradesh India.

Journal of Ocular Biology, Diseases, and Informatics
|March 6, 2014
PubMed
Summary

Topical bevacizumab effectively prevents bleb failure after trabeculectomy, significantly reducing intraocular pressure (IOP) for six months without medication. This glaucoma treatment shows promising results for sustained IOP control.

Keywords:
Topical bevacizumabTrabeculectomyWound healing

More Related Videos

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
07:13

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

Published on: December 7, 2016

12.8K

Related Experiment Videos

Last Updated: May 2, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.9K
An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
07:13

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

Published on: December 7, 2016

12.8K

Area of Science:

  • Ophthalmology
  • Glaucoma Surgery
  • Vascular Endothelial Growth Factor (VEGF) Inhibition

Background:

  • Trabeculectomy is a common glaucoma surgery to reduce intraocular pressure (IOP).
  • Bleb failure, often due to fibrosis, can compromise the long-term success of trabeculectomy.
  • Modulating wound healing processes is crucial for optimizing surgical outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of topical bevacizumab in preventing bleb failure post-trabeculectomy.
  • To assess the impact of bevacizumab on intraocular pressure (IOP) and bleb morphology.
  • To determine the duration of bevacizumab's effect on IOP control.

Main Methods:

  • A prospective study involving 23 patients undergoing trabeculectomy.
  • Postoperative instillation of topical bevacizumab (0.25 mg) five times over four weeks.
  • Comprehensive ophthalmic examinations including visual acuity, IOP, and bleb morphology at baseline and follow-up visits for six months.

Main Results:

  • All patients achieved target IOP, maintained for six months without anti-glaucoma medication.
  • Mean IOP decreased significantly from 27.27 ± 8.92 mmHg preoperatively to 8.77 ± 0.97 mmHg at 3 months and 9.27 ± 1.16 mmHg at 6 months (p=0.00).
  • A stable, low filtering bleb was observed throughout the study period; cup-to-disc ratio and visual fields remained unchanged.

Conclusions:

  • Post-trabeculectomy topical bevacizumab is effective in preventing bleb failure and achieving sustained IOP reduction.
  • Bevacizumab's anti-fibrotic properties appear to modulate wound healing stages, contributing to successful trabeculectomy outcomes.
  • Topical bevacizumab represents a safe and effective adjunct therapy for enhancing trabeculectomy success in glaucoma management.